Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | IDE | P14735 | 1/20 | 0.50 |
| ▸ | MPI | P34949 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30479099 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KDM4EMAPTGAACASP1 | |
| SCHEMBL8064218 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTGAACASP1 | |
| SCHEMBL5499463 | 0.81 | ALDH1A1 (0.61) | ALDH1A1KDM4EMAPTGAACASP1 | |
| SCHEMBL9250840 | 0.81 | KDM4E (0.53) | ALDH1A1KDM4EMAPTGAACASP1 | |
| SCHEMBL11187489 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTGAACASP1 | |
| SCHEMBL9457713 | 0.80 | KDM4E (0.53) | ALDH1A1KDM4EMAPTGAACASP1 | |
| SCHEMBL10685190 | 0.79 | KDM4E (0.64) | ALDH1A1KDM4EMAPTGAACASP1 | |
| SCHEMBL6702846 | 0.78 | KDM4E (0.68) | ALDH1A1KDM4EMAPTGAAIDE | |
| SCHEMBL2648556 | 0.78 | AHR (0.55) | ALDH1A1KDM4EMAPTGAACASP1 | |
| SCHEMBL28516422 | 0.77 | KDM4E (0.66) | ALDH1A1KDM4EMAPTGAACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122084713-A | Microelectrode, probe and electrochemical detection device | — | 2026-05-26 | — | — | CN | claimed |
| WO-2025068213-A1 | USE OF A MARKER SET FOR DETERMINING THE RISK OF HAVING OR DEVELOPING BLADDER CANCER | NUMARES AG (DE) | 2025-04-03 | — | — | WO | claimed |
| CN-117990671-A | Eu (Eu)3+Application of complex in fluorescence detection of hydroxy indoleacetic acid | 广州大学 | 2024-05-07 | — | — | CN | claimed |
| EP-3522172-B1 | METHOD FOR ASSESSING A NEUROPSYCHIATRIC CONDITION OF A HUMAN SUBJECT | CHILDRENS HOSPITAL MED CT (US) | 2021-10-20 | — | — | EP | claimed |
| EP-3522172-A1 | METHOD FOR ASSESSING A NEUROPSYCHIATRIC CONDITION OF A HUMAN SUBJECT | Cincinnati Children's Hospital Medical Center (US) | 2019-08-07 | — | — | EP | claimed |
| US-20190131015-A1 | COMPUTER IMPLEMENTED SYSTEM AND METHOD FOR ASSESSING A NEUROPSYCHIATRIC CONDITION OF A HUMAN SUBJECT | CHILDREN'S HOSPITAL MEDICAL CENTER | 2019-05-02 | — | — | US | claimed |
| EP-2425356-B1 | COMPUTER IMPLEMENTED SYSTEM AND METHOD FOR ASSESSING A NEUROPSYCHIATRIC CONDITION OF A HUMAN SUBJECT | CINCINNATI CHILDRENS HOSPITAL MEDICAL CENTER (US) | 2019-03-13 | — | — | EP | claimed |
| US-10204707-B2 | Computer implemented system and method for assessing a neuropsychiatric condition of a human subject | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-02-12 | — | — | US | claimed |
| EP-2425356-A1 | COMPUTER IMPLEMENTED SYSTEM AND METHOD FOR ASSESSING A NEUROPSYCHIATRIC CONDITION OF A HUMAN SUBJECT | Cincinnati Children's Hospital Medical Center (US) | 2012-03-07 | — | — | EP | claimed |
| US-20120041911-A1 | COMPUTER IMPLEMENTED SYSTEM AND METHOD FOR ASSESSING A NEUROPSYCHIATRIC CONDITION OF A HUMAN SUBJECT | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2012-02-16 | — | — | US | claimed |
| WO-2011138142-A1 | COMPOSITIONS AND USE OF SULFASALAZINE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2011-11-10 | — | — | WO | claimed |
| WO-2010126867-A1 | COMPUTER IMPLEMENTED SYSTEM AND METHOD FOR ASSESSING A NEUROPSYCHIATRIC CONDITION OF A HUMAN SUBJECT | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2010-11-04 | — | — | WO | claimed |
| CN-122084713-A | Microelectrode, probe and electrochemical detection device | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250377363-A1 | METHODS RELATING TO DIAGNOSING STABILITY FOLLOWING RENAL TRANSPLANTATION | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250228842-A1 | USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROME | Crinetics Pharmaceuticals, Inc. | 2025-07-17 | — | — | US | disclosed |
| US-12329726-B2 | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-06-17 | — | — | US | disclosed |
| WO-1993004373-A1 | CALCIUM RECEPTOR ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
| EP-0284725-A2 | Indoxyl-beta-d-glucuronide and method for making | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1988-10-05 | — | — | EP | disclosed |
| US-4083982-A | 3-(PARA-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3-PHENYL-PROPYLAMINE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1978-04-11 | — | — | US | disclosed |
| US-4035511-A | 3-(P-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3-PHENYLPROPYLAMINE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228842-A1 | USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROME | SSTR4, SSTR5, SSTR2 | ALDH1A1 3940/4885KDM4E 2881/4885MAPT 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.